CNX-2006 is primarily utilized in the field of oncology as a targeted therapeutic agent. It is designed to inhibit specific pathways involved in cancer cell proliferation and survival, making it a promising candidate for the treatment of various malignancies. The compound is often used in preclinical and clinical studies to evaluate its efficacy in reducing tumor growth and enhancing the effectiveness of existing cancer therapies. Additionally, CNX-2006 is being explored for its potential to overcome drug resistance in certain cancers, offering new avenues for combination treatments. Its application extends to research settings where it aids in understanding the molecular mechanisms underlying cancer progression and response to treatment.